1. Home
  2. PMAX vs LYRA Comparison

PMAX vs LYRA Comparison

Compare PMAX & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Powell Max Limited

PMAX

Powell Max Limited

HOLD

Current Price

$2.04

Market Cap

6.4M

Sector

N/A

ML Signal

HOLD

Logo Lyra Therapeutics Inc.

LYRA

Lyra Therapeutics Inc.

HOLD

Current Price

$1.19

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMAX
LYRA
Founded
2019
2005
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
5.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PMAX
LYRA
Price
$2.04
$1.19
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
15.0K
68.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,534,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.08
52 Week High
$5.20
$37.50

Technical Indicators

Market Signals
Indicator
PMAX
LYRA
Relative Strength Index (RSI) 36.26 34.86
Support Level $1.61 $1.21
Resistance Level $2.67 $1.52
Average True Range (ATR) 0.16 0.18
MACD -0.05 0.03
Stochastic Oscillator 0.15 51.12

Price Performance

Historical Comparison
PMAX
LYRA

About PMAX Powell Max Limited

Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: